Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.69 +2.4%	$1.59	$1.03 ▼ $2.41	$52.72M	-0.53	423,646 shs	103,742 shs
LTRN Lantern Pharma	$4.57	$3.82	$2.55 ▼ $6.12	$49.35M	1.6	391,340 shs	72,012 shs
PHGE BiomX	$0.56 -24.9%	$0.45	$0.34 ▼ $2.40	$12.99M	1.42	347,190 shs	53,300 shs
PRLD Prelude Therapeutics	$0.87 -7.9%	$0.87	$0.61 ▼ $5.95	$49.12M	1.22	135,234 shs	80,871 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	+9.74%	+4.32%	+1.20%	-13.55%
LTRN Lantern Pharma	0.00%	-8.42%	+6.78%	+37.65%	+15.99%
PHGE BiomX	0.00%	+16.35%	+42.67%	+2.78%	-69.84%
PRLD Prelude Therapeutics	0.00%	+1.46%	+6.10%	-1.49%	-83.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	2.9528 of 5 stars	3.5	5.0	2.8	0.0	0.6
LTRN Lantern Pharma	2.938 of 5 stars	3.5	3.0	3.9	0.8	0.6
PHGE BiomX	2.445 of 5 stars	3.5	0.0	2.1	0.8	1.3
PRLD Prelude Therapeutics	3.0575 of 5 stars	3.5	3.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	166.27% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	447.05% Upside
PHGE BiomX	3.00	Buy	$21.00	3,683.78% Upside
PRLD Prelude Therapeutics	3.00	Buy	$4.50	417.24% Upside

Current Analyst Ratings Breakdown

Latest PHGE, ATNM, LTRN, and PRLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.16 per share	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A
PRLD Prelude Therapeutics	$7M	7.02	N/A	N/A	$2.39 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
LTRN Lantern Pharma	-$20.78M	-$1.78	N/A	N/A	N/A	N/A	-99.89%	-81.58%	N/A
PHGE BiomX	-$28.32M	-$1.36	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A
PRLD Prelude Therapeutics	-$127.17M	-$1.64	N/A	N/A	N/A	N/A	-95.37%	-72.56%	11/5/2025 (Estimated)

Latest PHGE, ATNM, LTRN, and PRLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	-$0.41	+$0.04	-$0.41	N/A	N/A
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
LTRN Lantern Pharma	N/A	3.52	4.86
PHGE BiomX	0.51	2.84	2.84
PRLD Prelude Therapeutics	N/A	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
LTRN Lantern Pharma	28.62%
PHGE BiomX	40.57%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
LTRN Lantern Pharma	7.31%
PHGE BiomX	1.17%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
LTRN Lantern Pharma	20	10.80 million	10.01 million	Optionable
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.38 million	Optionable

PHGE, ATNM, LTRN, and PRLD Headlines

Recent News About These Companies

Prelude Cuts Q2 Losses and Costs 13%

August 14 at 12:13 PM | aol.comA

Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development

August 14 at 12:13 PM | msn.com

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14 at 7:00 AM | globenewswire.com

Can Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?

August 11, 2025 | finance.yahoo.com

Prelude Therapeutics (PRLD) Projected to Post Earnings on Monday

August 10, 2025 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher - Time to Buy?

July 26, 2025 | marketbeat.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

Prelude Therapeutics CEO buys $467K in common stock

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, ATNM, LTRN, and PRLD Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.69 +0.04 (+2.42%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.68 0.00 (-0.30%)

As of 08/15/2025 05:11 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Lantern Pharma NASDAQ:LTRN

$4.57 0.00 (0.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.67 +0.10 (+2.19%)

As of 08/15/2025 07:41 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

BiomX NYSEMKT:PHGE

$0.56 -0.18 (-24.90%)

Closing price 08/15/2025 03:55 PM Eastern

Extended Trading

$0.54 -0.02 (-2.88%)

As of 08/15/2025 07:54 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Prelude Therapeutics NASDAQ:PRLD

$0.87 -0.08 (-7.94%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.89 +0.02 (+2.64%)

As of 08/15/2025 06:54 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time